КЮРЛЕД-ЛП

Product Overview

About КЮРЛЕД-ЛП

КЮРЛЕД-ЛП is a prescription medication containing the active ingredients Sofosbuvir and Ledipasvir, used in the treatment of chronic hepatitis C virus (HCV) infection. It is a combination of a nucleotide analog inhibitor (Sofosbuvir) and a NS5A inhibitor (Ledipasvir), which work together to inhibit the replication of the HCV virus in the liver.

Key Benefits & Uses

• Treatment of chronic hepatitis C virus (HCV) infection, including genotypes 1 and 4.
• Combination therapy with other medications to achieve sustained virologic response (SVR) in patients with HCV infection.
• Used in patients with compensated cirrhosis and without cirrhosis, as well as in patients with or without HIV co-infection.

Active Ingredient & Action

Sofosbuvir is a nucleotide analog inhibitor that works by binding to the NS5B polymerase of the HCV virus, preventing the replication of the virus. Ledipasvir is a NS5A inhibitor that binds to the NS5A protein of the HCV virus, preventing the virus from replicating and causing liver damage. The combination of Sofosbuvir and Ledipasvir in КЮРЛЕД-ЛП provides a synergistic effect, increasing the efficacy of the treatment and reducing the risk of resistance.

Important Notes

КЮРЛЕД-ЛП is a prescription medication and should only be used under the guidance of a healthcare professional. Patients should be tested for HCV genotypes and HIV co-infection before starting treatment. Common side effects of КЮРЛЕД-ЛП include fatigue, headache, and nausea. Patients should report any side effects to their healthcare provider and follow the recommended dosage and treatment regimen to achieve optimal results.